Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pralatrexate
Drug ID BADD_D01814
Description Pralatrexate is an antimetabolite for the treatment of relapsed or refractory peripheral T-cell lymphoma. It is more efficiently retained in cancer cells than methotrexate. FDA approved on September 24, 2009.
Indications and Usage Treatment of relapsed or refractory peripheral T-cell lymphoma.
Marketing Status Prescription
ATC Code L01BA05
DrugBank ID DB06813
KEGG ID D05589
MeSH ID C418863
PubChem ID 148121
TTD Drug ID D02LWU
NDC Product Code 72893-003; 48818-001; 47848-045; 68554-0071; 53183-4020; 72893-005; 65392-2510
Synonyms 10-propargyl-10-deazaaminopterin | pralatrexate
Chemical Information
Molecular Formula C23H23N7O5
CAS Registry Number 146464-95-1
SMILES C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myalgia15.05.02.0010.000533%
Mycosis fungoides23.07.04.008; 16.17.03.001; 01.11.03.0010.000799%Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Neutropenia01.02.03.0040.000799%Not Available
Neutrophil count decreased13.01.06.0100.001066%
Night sweats23.02.03.006; 08.01.03.031--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain in extremity15.03.04.010--
Pancytopenia01.03.03.0030.001865%Not Available
Platelet count decreased13.01.04.0010.002664%
Pneumonia22.07.01.003; 11.01.09.0030.000799%Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.0030.001598%
Rash23.03.13.0010.000799%Not Available
Sepsis11.01.11.0030.000208%
Skin disorder23.03.03.0070.000533%Not Available
Skin exfoliation23.03.07.0030.000533%Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.03.020; 23.03.01.007; 12.03.01.0140.001332%
Stomatitis07.05.06.0050.004263%
Tachycardia02.03.02.007--Not Available
Thrombocytopenia01.08.01.0020.000533%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Tumour lysis syndrome14.05.01.004; 16.32.03.0020.000139%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Vomiting07.01.07.003--
White blood cell count decreased13.01.06.0120.000533%
Malignant neoplasm progression16.16.01.0050.001112%Not Available
Adverse event08.06.01.010--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages